Aankondiging • 7h
Exosens Reiterates Earnings Guidance for the Year 2026 Exosens reiterated earnings guidance for the year 2026. For the year, the company is on track to deliver on 2026 guidance now expecting revenue and adjusted EBITDA to be towards the upper end of their respective ranges. Revenue in the range of €520 million to €540 million. Valuation Update With 7 Day Price Move • Jul 23
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €64.10, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 31x in the Aerospace & Defense industry in Germany. Total returns to shareholders of 65% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €90.88 per share. Buy Or Sell Opportunity • Jun 15
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 16% to €60.10. The fair value is estimated to be €77.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 96%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 16% per annum over the same time period. Aankondiging • May 29
Exosens Approves Cash Dividend, Payable on 29 May 2026 Exosens at its Combined General Meeting held on 22 May 2026, approved the payment of a cash dividend of €0.30 per share, with payment commencing on 29 May 2026. Upcoming Dividend • May 21
Upcoming dividend of €0.30 per share Eligible shareholders must have bought the stock before 27 May 2026. Payment date: 29 May 2026. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (4.5%). Lower than average of industry peers (0.9%). Declared Dividend • May 21
Dividend increased to €0.30 Dividend of €0.30 is 200% higher than last year. Ex-date: 27th May 2026 Payment date: 29th May 2026 Dividend yield will be 0.5%, which is lower than the industry average of 1.4%. Payout Ratios Payout ratio: 22%. Cash payout ratio: 30%. Aankondiging • Apr 27
Exosens (ENXTPA:EXENS) acquired Emberion Oy. Exosens (ENXTPA:EXENS) acquired Emberion Oy on April 24, 2026. For the period ending December 31, 2025, Emberion Oy reported total revenue of approximately €0.7 million.
Exosens (ENXTPA:EXENS) completed the acquisition of Emberion Oy on April 24, 2026. Aankondiging • Apr 21
Exosens, Annual General Meeting, May 22, 2026 Exosens, Annual General Meeting, May 22, 2026. Location: 83 avenue marceau, paris France Aankondiging • Jan 08
Theon International Plc (ENXTAM:THEON) completed the acquisition of 9.8% stake in Exosens (ENXTPA:EXENS) from Invest Gamma, HLD Europe S.C.A. and Invest Prince Henri SCA. Theon International Plc (ENXTAM:THEON) entered into a definitive agreement to acquire 9.8% stake in Exosens (ENXTPA:EXENS) from Invest Gamma, HLD Europe S.C.A. and Invest Prince Henri SCA for approximately €270 million on October 11, 2025. The purchase price is a cash consideration of €268.7 million corresponding to €54 per share. Following the completion of the transaction, THEON will become the second largest shareholder in EXOSENS, after Groupe HLD. In connection with the transaction, UBS Europe SE and Citibank Europe PLC have agreed to provide a bridge facility, which is intended to be refinanced with a combination of debt and newly issued equity within existing shareholders’ authorizations.
The closing of the transaction remains subject to regulatory notifications in a selected number of countries and is expected to take place in early Q1 2026.
UBS Europe SE acted as financial advisor for Theon International Plc. Clifford Chance LLP acted as legal advisor for Theon International Plc.
Theon International Plc (ENXTAM:THEON) completed the acquisition of 9.8% stake in Exosens (ENXTPA:EXENS) from Invest Gamma, HLD Europe S.C.A. and Invest Prince Henri SCA on January 7, 2026. Aankondiging • Jan 06
Exosens to Report Q3, 2026 Results on Oct 27, 2026 Exosens announced that they will report Q3, 2026 results on Oct 27, 2026 Aankondiging • Oct 28
Exosens (ENXTPA:EXENS) acquired Noxant SAS. Exosens (ENXTPA:EXENS) acquired Noxant SAS on March 13, 2025.
Exosens (ENXTPA:EXENS) completed the acquisition of Noxant SAS on March 13, 2025. Aankondiging • Sep 10
Exosens Launches Its New 5G Image Intensifier Tube Exosens announced the launch of its 5G image intensifier tube, offering unrivalled overall performance in the field of night vision. 5G tubes introduce major advances that could redefine the operational capabilities of armed forces. They offer a significant improvement in overall performance (known as FOM) of 30% and an increase of up to 35% in detection ranges, regardless of the night level (from 1 to 5) compared to current standard intensifier tubes. With this new technology, visual comfort is unparalleled: thanks to innovations in manufacturing processes and high-end components, 5G tubes offers even sharper images. There is a significant reduction in "noise" or "flicker," especially in low-light conditions, by improving the perception of textures, contrasts, and depth. This increase in comfort significantly reduces visual fatigue and mental strain, and enhances soldier mobility through improved perception of the environment and ground contours. With the war in Ukraine demonstrating the need to modernize the equipment of European land forces, 5G technology is set to become the product of choice for special forces and the future standard for night vision within all armed forces. With orders already confirmed ahead of its official launch, 5G is already proving popular with its first users. The design of 5G is also a French industrial achievement: it is the product of cutting-edge innovations, mastered from end-to-end in France, which will contribute to the upgrading and strengthening of the European armed forces and their allies. This innovation reinforces the ability of armed forces to act with precision, efficiency, and security in increasingly complex environments. Aankondiging • Aug 28
Exosens (ENXTPA:EXENS) signed an agreement to acquire Phasics. Exosens (ENXTPA:EXENS) signed an agreement to acquire Phasics on August 27, 2025. Aankondiging • May 24
Exosens announces Annual dividend, payable on May 30, 2025 Exosens announced Annual dividend of EUR 0.1000 per share payable on May 30, 2025, ex-date on May 28, 2025 and record date on May 29, 2025. Aankondiging • Apr 19
Exosens, Annual General Meeting, May 23, 2025 Exosens, Annual General Meeting, May 23, 2025. Location: 83 avenue marceau, paris France Aankondiging • Mar 22
Exosens to Report Q3, 2025 Results on Oct 27, 2025 Exosens announced that they will report Q3, 2025 results on Oct 27, 2025 Aankondiging • Mar 04
Exosens Proposes Cash Dividend for the Fiscal Year 2024 Exosens Board of Directors decided, during its meeting on 28 February 2025, to propose the payment of a €0.10 cash dividend per share for the 2024 fiscal year. This amount will be subject to the approval of the Annual General Shareholders' Meeting, which will take place on 23 May 2025. Aankondiging • Jan 24
Exosens' Brand Photonis Launches Two Market-Leading Solutions to Advance Single Photon Detection and Imaging Applications Photonis, a leading brand of Exosens and global leader in advanced photon detection and imaging solutions announced the launch of Crickettm Pro and PhotonPixtm. Designed to redefine the possibilities of single photon detection and imaging, these cutting-edge solutions empower researchers and industry professionals to achieve unparalleled performance across applications such as biomedical imaging, quantum science, and high-energy physics. These technologies will officially debut at SPIE Photonics West 2025 in San Francisco, CA. The Crickettm Pro brings unprecedented imaging capabilities for low-light and single-photon imaging applications. This innovative, plug-and-play image intensifier adapter easily fits any professional, scientific, F-Mount camera, delivering high resolution and ultra-high-speed functionality for demanding low-light applications. Key features of the Crickettm Pro include: Expanded 25 mm active detection area; High-speed gating as fast as 3 nanoseconds; Rem remarkable 3 MHz Burst or 30kHz repetition rate; Matched with High-performance Photonis Image Intensifier; F-Mount lens/camera interface; Fully integrated power and gating electronics. With these enhancements, Crickettm Pro sets a new benchmark for scientific imaging, providing precise, rapid, and reliable performance tailored for researchers and industry professionals. PhotonPixtm: Ultra High-Count Rate Module for Single-Photon Detection; PhotonPix also introduces PhotonPixtm, a high-count rate MCP-PMT-based plug-and-play module engineered for ultra-high timing precision single-photon detection. Combining technology with user-centric design, PhotonPix offers: An O8 mm sensitive area; Extreme-low dark count rate as low as 20 cps; Count rates exceeding 200 MHz in Burst mode, making it ideal for high-demand applications; Timing resolution below 15 ps for unmatched precision; PhotonPixtm is ideal for ultra-fast Single Photon Detection and time-correlated applications such as LIDAR, Photon Entanglement, or Lifetime Imaging. The module's versatility accommodates various high-quantum-efficiency (Hi-QE) photocathodes from Photonis, covering the spectrum range from 150nm to 900nm, making it the perfect fit for researchers and industry professionals. Aankondiging • Nov 19
Exosens Reportedly in Talks to Buy Noxant Exosens (ENXTPA:EXENS) has entered into exclusive talks on the acquisition for an undisclosed amount of Noxant (Noxant SAS). The contemplated deal is aimed at bolstering Exosens' technology platform with the addition of advanced cooled infrared camera cores for OEM partners, particularly in the Midwave Infrared (MWIR) range. Noxant’s technology serves applications in surveillance, scientific research and industrial testing, as well as in gas detection. The parties anticipate finalising a deal in the coming months, subject to the completion of the consultation of the employees’ representative body of Noxant and customary regulatory approvals. Aankondiging • Oct 29
Exosens to Report Fiscal Year 2024 Results on Mar 03, 2025 Exosens announced that they will report fiscal year 2024 results Pre-Market on Mar 03, 2025 Aankondiging • Oct 28
Exosens Provides Revenue Guidance for 2024 Exosens provided revenue guidance for 2024. For the year, the company expects high-teens organic revenue growth and around 30% total revenue growth including 2024 acquisitions. Reported Earnings • Sep 03
First half 2024 earnings released First half 2024 results: Net income: €2.90m (up €2.90m from 1H 2023). Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Aerospace & Defense industry in Germany. Aankondiging • Sep 03
Exosens (ENXTPA:EXENS) acquired LR Tech Inc. Exosens (ENXTPA:EXENS) acquired LR Tech Inc. on September 1, 2024. Exosens' product line in cooled infrared technology is intended to be enhanced by this acquisition.
Exosens (ENXTPA:EXENS) completed the acquisition of LR Tech Inc. on September 1, 2024. Aankondiging • Aug 01
Exosens (ENXTPA:EXENS) acquired Centronic Limited. Exosens (ENXTPA:EXENS) acquired Centronic Limited on August 1, 2024.
Exosens (ENXTPA:EXENS) completed the acquisition of Centronic Limited on August 1, 2024. Aankondiging • Jul 24
Exosens Reiterates Revenue Guidance for 2024 Exosens reiterated revenue guidance for 2024. Based on this strong revenue growth in the first semester, the company reiterates its outlook of high-teens organic revenue growth in the upper 15%-20% range and around 30% of total revenue growth including the contribution over 12 months of acquisitions made in 2024. Board Change • Jun 13
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 
